Business Context and Reporting Period
This Form 8-K is filed by Biocardia, Inc. (BCDA) on June 12, 2026. The report addresses the Company's status regarding Nasdaq Listing Rule 5550(b)(1), which mandates a minimum stockholders' equity of $2,500,000 for continued listing. The filing updates a previous notification received on April 10, 2026, indicating the Company had fallen below this threshold.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. However, it discloses specific capital raising activities and equity status:
- Stock Sale (April 1 - June 5, 2026): Sold 4,004,330 shares of common stock via an "At The Market" offering.
- Average Share Price: $1.27.
- Net Proceeds: $4.9 million (after fees and expenses).
- Stockholders' Equity: The Company states that as of the report date, stockholders' equity exceeds the $2.5 million minimum requirement.
Material Changes
The primary material change is the restoration of compliance with Nasdaq listing standards. Following a deficiency notice in April 2026, the Company submitted a compliance plan on May 25, 2026, and received an extension from Nasdaq until October 7, 2026. Subsequent equity raises totaling $4.9 million in net proceeds have allowed the Company to believe it has regained compliance with the minimum equity requirement.
Outlook, Risks, and Contingencies
Outlook: The Company believes it has met the $2.5 million stockholders' equity requirement as of June 12, 2026. Nasdaq will continue to monitor ongoing compliance.
Risks: If the Company fails to evidence compliance in its next periodic report, it may be subject to delisting. The filing includes standard forward-looking statement disclaimers regarding the uncertainty of maintaining listing standards.
Investor Verification Checklist
- Verify the exact stockholders' equity balance in the Company's next periodic report (10-Q or 10-K) to confirm sustained compliance.
- Review the "At The Market" offering agreement terms with H.C. Wainwright & Co. for any remaining capacity or restrictions.
- Monitor future Nasdaq communications regarding the Company's listing status post-October 7, 2026.
- Check the March 24, 2026 Form 10-K for detailed historical financials and risk factors referenced in this filing.